Our Co-founder & COO Andreas Ingemann Jensen and Project & Business Developer Rocío García Vázquez will be attending the 13th International Symposium on Targeted Alpha Therapy (TAT 13) in Rio from April 14 – 16.
At Tetrakit Technologies, we’re working with tetrazine-based click chemistry to enable fast and high-yield radiolabeling of any cancer-targeting biomolecule with radiohalogens such as astatine. We’re continuing to build our pipeline of ²¹¹At-based assets with preclinical evaluation planned for our lead program ²¹¹At-DualFAPi-5. We’re always open to new collaborations and partnerships to label targeting molecules with radiohalogens using the TetraKit Platform.
If you’re interested in our astatine pipeline or potential collaborations, we’d be glad to connect and discuss further. Feel free to reach out by email.
📧 andreas.jensen@tetrakit.com
📧 rocio.garcia@tetrakit.com
